Biomemory’s acquisition of Catalog Technologies gives it key patents and infrastructure. Will it be enough to make DNA data storage commercially viable for enterprises?
Biomemory’s acquisition of Catalog Technologies gives it key patents and infrastructure. Will it be enough to make DNA data storage commercially viable for enterprises?
